GH Research (NASDAQ:GHRS) Shares Gap Up to $11.66

GH Research PLC (NASDAQ:GHRS)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $11.66, but opened at $11.96. GH Research shares last traded at $11.96, with a volume of 2,286 shares trading hands.

Analyst Ratings Changes

Several research firms have recently weighed in on GHRS. Canaccord Genuity Group lifted their target price on shares of GH Research from $30.00 to $31.00 and gave the company a “buy” rating in a report on Monday, May 6th. HC Wainwright reissued a “buy” rating and issued a $40.00 price target on shares of GH Research in a research note on Tuesday, May 7th.

GH Research Stock Performance

The business’s 50 day moving average is $12.34 and its 200-day moving average is $9.70. The stock has a market cap of $626.96 million, a price-to-earnings ratio of -19.44 and a beta of 0.86.

GH Research (NASDAQ:GHRS) last released its quarterly earnings results on Friday, May 3rd. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.07. Sell-side analysts anticipate that GH Research PLC will post -0.84 EPS for the current fiscal year.

Institutional Investors Weigh In On GH Research

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. BVF Inc. IL boosted its stake in GH Research by 12.1% during the 4th quarter. BVF Inc. IL now owns 10,400,158 shares of the company’s stock worth $60,321,000 after purchasing an additional 1,125,000 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its stake in GH Research by 14.6% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 106,363 shares of the company’s stock worth $617,000 after purchasing an additional 13,579 shares during the last quarter. RTW Investments LP boosted its stake in GH Research by 53.4% during the 3rd quarter. RTW Investments LP now owns 3,327,129 shares of the company’s stock worth $33,438,000 after purchasing an additional 1,158,172 shares during the last quarter. AdvisorShares Investments LLC boosted its stake in GH Research by 4.3% during the 4th quarter. AdvisorShares Investments LLC now owns 48,300 shares of the company’s stock worth $280,000 after purchasing an additional 1,977 shares during the last quarter. Finally, Lynx1 Capital Management LP boosted its stake in GH Research by 80.1% during the 1st quarter. Lynx1 Capital Management LP now owns 3,310,563 shares of the company’s stock worth $35,291,000 after purchasing an additional 1,471,946 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).